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Abstract: The demand has increased for sophisticated molecular tools with improved detection limits.
Such molecules should be simple in structure, yet stable enough for clinical applications. Nucleic acid
aptamers (NAAs) represent a class of molecules able to meet this demand. In particular, aptamers,
a class of small nucleic acid ligands that are composed of single-stranded modified/unmodified
RNA/DNA molecules, can be evolved from a complex library using Systematic Evolution of Ligands
by EXponential enrichment (SELEX) against almost any molecule. Since its introduction in 1990,
in stages, SELEX technology has itself undergone several modifications, improving selection and
broadening the repertoire of targets. This review summarizes these milestones that have pushed the
field forward, allowing researchers to generate aptamers that can potentially be applied as therapeutic
and diagnostic agents.
Keywords: SELEX; nucleic acid aptamers; cell-surface markers
1. Introduction
The elevated expression level of cell-surface proteins in response to disease is a key concept
underlying the development of target-specific molecular probes [1,2]. Cell-surface proteins are
primarily engaged in signal transduction and ligand binding. In the disease state, receptor molecules at
the cell surface respond to altered biological activity by exhibiting different levels of expression [3]. It is
this differential expression that allows researchers and clinicians to distinguish between diseased and
normal cells. Detecting this variable expression of surface markers has been extensively used in many
clinical applications as an avenue to diagnose and treat specific diseases [4–6]. From a fundamental
point of view, molecular probes able to recognize such markers would be a key advantage, and, indeed,
the demand for such sophisticated molecular tools is increasing.
In particular, nucleic acid aptamers (NAAs) represent a class of molecules able to meet this
demand. NAAs are synthetic DNA or RNA molecules with the ability to recognize a specific molecule
with high affinity and specificity [7,8]. The nature of the molecular recognition between the aptamer and
its target is based on non-covalent interactions. Specifically, electrostatic and hydrophobic interactions,
as well as shape complementarity, govern the aptamer’s recognition of its target [9]. In the context of
clinical applications, NAAs are attractive for their unique pharmacokinetics properties and their easily
modifiable synthetic nature, which has allowed the incorporation of a wide variety of functional groups
at precise positions in aptamer molecules without compromising their affinity or specificity [10–13].
This property is especially important for aptamers used in sensors, as diagnostic agents, or as drug
conjugates. For example, based on a study conducted by Watson et al., clearance of an aptamer
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against L-selectin could be modulated by simply modifying an aptamer with high-molecular-weight
poly-(ethylene glycol) in vivo, utilizing animal models to reduce renal clearance and extend circulation
time [14]. These properties are unique to aptamers, and they have been successfully utilized in
designing new versatile molecules aimed at a multitude of applications [15–19]. Most importantly,
recent advances in oligonucleotide-based therapeutics, such as antisense technology and microRNA
therapeutics, have spurred a renewed demand for the development of novel aptamer-based targeting
molecules [20–22]. Utilization of NAAs as carriers of siRNA or microRNA can eliminate tedious
conjugation methods, thus allowing one molecule to serve as both the drug and targeting agent. In fact,
both target recognition and therapeutic moiety can be combined in one step using a solid-state synthesis
in an automated oligonucleotide synthesizer. A number of examples have shown the versatility of
aptamers discovered against cell-surface markers as delivery agents for microRNA, and siRNA, both
in vitro and in vivo [7,23–26].
The concept of in vitro evolution of nucleic acid molecules was introduced in 1990 from three
independent groups. Robertson and Joyce introduced in vitro selection of more efficient catalytic
RNA compared to wild-type Tetrahymena ribozyme [27]. Tuerk and Gold reported the isolation of
high-affinity RNA ligands against T4 DNA polymerase and coined the term Systematic Evolution of
Ligands by EXponential enrichment, or SELEX [28]. Finally, Ellignton and Soztak demonstrated that
RNA ligands could be enriched from a pool of RNA molecules against organic dye molecules and
defined these artificial RNA ligands as aptamers [29]. Thus, by combining the rules of combinatorial
library screening with in vitro evolution, these studies demonstrated, for the first time, that nucleic
acid ligands could be isolated against a wide range of molecules. Since these initial reports of
SELEX, many independent reports have shown that aptamers can be evolved from a complex
library using SELEX against almost any molecule, especially molecules that are not known as
oligonucleotide-binding molecules [7,19,22,30]. Establishing the SELEX method in generating hundreds
of aptamers for use in therapeutics or diagnostics was initially successful [8]. Nonetheless, only one
aptamer has thus far been approved by the FDA for neovascular age-related macular degeneration
(Macugen (pegaptanib)) [31,32]. Several aptamers are currently being evaluated in various clinical
trials, ranging from phase 1 to 3 [33].
The SELEX process involves three interconnected steps. Step one involves the repeated incubation
of a library with a specific target to allow binding of high-affinity aptamers. Step two involves the
separation of high- from low-affinity binders. Step three involves the amplification of high-affinity
binders utilizing polymerase chain reaction (PCR). This process is repeated until the high-affinity
aptamers are enriched in the selection pool. The basis of the SELEX process is mainly rooted in
the ability of high-affinity binders to survive in a SELEX pool through several rounds of selection.
External selection pressures to enhance selectivity and affinity of the survivors are implemented
throughout the process. As discussed by Eaton et al., NAAs have been identified that can distinguish
between L and D amino acids and between reduced and oxidized cofactors [9]. This demonstrates
the level of specificity that can be achieved by aptamers. However, it is important to point out that
such specificity can also be detrimental when a single purified protein is used as the SELEX target.
SELEX is successful in generating NAA sequences towards a purified protein, but it is well known
that the binding of these NAAs can only be mimicked in conditions used for aptamer selection.
In other words, aptamers selected using purified protein may not recognize the same protein at its
endogenous levels or conditions in a cell. Many aptamers were reported during the first decade
after the introduction of SELEX, but most aptamers discovered against purified protein targets failed
to recognize the same protein in its native environment. Nonetheless, a few aptamers have been
successful and are worth mentioning. For example, an aptamer against extracellular domains of
prostate-specific membrane antigen (PSMA) has been successful and used in many proof-of-concept
applications [34–36]. As noted previously, the SELEX method itself has been updated many times by
allowing modifications that changed or improved the selection process. This review will highlight
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advancements in SELEX technology towards complex targets (Figure 1), in particular those aptamers
that may now potentially be applied as theranostic agents.Molecules 2017, 22, 215  3 of 12 
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2. Complex Target SELEX
Successful selection of high-affinity aptamers depends on consistent, unperturbed presentation
of the targeting pitope [37]. Therefo e, during the SELEX process, it s necessary t maintain
a uniform, fold state of the desire protein to successfully obtain high-affinity aptamers. Mo ris et al.
identified this problem and developed a variant of the original SELEX called complex target SELEX,
which particularly addresses the target [38]. For the first time, these authors demonstrated that human
red blood cell membrane preparations (RBC ghosts) can be used in place of purified membrane proteins
as long as the potential target(s) on RBC remained unchanged during the in vitro selection process [38].
Based on these results, it was postulated that the epitope remained unchanged, either by mis-folding
or other unknown salt effects, thereby facilitating selective identification of aptamers against RBC
membranes [38]. A similar approach was utilized for the original SELEX with 25 rounds using
nitrocellulose filt r binding as the method of s parating high- from low-affinity binders. The approach
carried out by Morris et al. led to the dis overy of 41 sequences, which c ul e categorized into six
distinct families based on common motifs among the sequences [38]. The truncated motifs modified
with photo-crosslinking functional groups, followed by SDS-PAGE, and distinctly identified protein
complexes specifically cross-linked to aptamers identified by complex target SELEX. This was the
first study to demonstrate that (1) aptamers against multiple targets could be identified utilizing
multi-epitope membrane preparations; (2) the SELEX library is sufficiently diverse to allow competition
between potential aptamer ligands towards one target; (3) multiple aptamers could be selected towards
multiple targets. The authors reported that the aptamers selected by complex target SELEX bind to
proteins based on gel-electrophoresis analysis, but the authors did not identify the protein.
3. Crossover- or (Hybrid)-SELEX
To enhance the selecti n efficiency and avoid generating aptamers against potential co-receptors
of the biomarker of interest was introduced through a variant of SELEX termed hybrid- or
crossover-SELEX [39]. This approach is especially useful in generating NAAs against known
biomarkers. Demonstrated by multiple groups, crossover-SELEX first enriches an aptamer pool against
a whole cell expressing the target of interest, followed by further enrichment of the aptamers against
the recombinant purified biomarker [40]. Using this method, an RNA aptamer against Tenascin C
(TN-C), a glycoprotein that, in humans, is encoded by the TNC gene and is over-expressed on U251
glioblastoma cells, was identified [39]. A reverse crossover-SELEX was later employed to identify
anti-Transferrin aptamers [41].
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4. Tumor Cell SELEX
Later, Daniels et al. demonstrated that aptamers could be generated against antigens presented
by a monolayer of tumor cells [42]. To accomplish this, a glioblastoma cell line, U251, was used
as the target for a SELEX library of single-stranded DNA (ssDNA). It was shown that whole cells
could be utilized as targets in SELEX experiments. With the objective of a priori identification of
biologically important targets and the potential development of aptamers with in vivo targeting ability,
the authors further demonstrated that an ssDNA pool could be evolved with 21 iterative rounds
against a monolayer of glioblastoma cells. One aptamer identified during the selection, termed GBI-10,
represented 10% of the sequences among sequences obtained by sequenced SELEX pool. Next, GBI-10
was used as a capturing agent and affinity purification was utilized to identify the target of the aptamer.
The identified target of GBI-10 is Tenascin C, which is a hexameric protein expressed extracellularly in
the tumor matrix. However, since the selection was performed at 4 ◦C, the identified aptamers did not
recognize the target at physiological conditions.
By utilizing mono-layered tumor cells as the target, tumor cell SELEX demonstrated that
aptamers could be generated against distinct known epitopes expressed on U251 cells. This study
also demonstrated the use of affinity pull-down assays, followed by mass spectrometry to identify
the aptamer’s target. The key significance of this method is the demonstration that NAAs can be
developed against surface markers in their native state, which is a particularly important feature, given
that these trans-membrane proteins could face the possibility of mis-folding in a purified form.
These examples show the ability of SELEX to identify aptamers against cell-surface
proteins utilizing whole cells, thereby opening the path toward developing more sophisticated
selection approaches.
5. Live Cell-SELEX Utilizing Flow Cytometry for Biomarker Discovery
To develop aptamer-based molecular tools able to distinguish differences between healthy and
diseased cells at the molecular level, Shangguan et al. developed a variant of complex target SELEX
termed live cell–SELEX [43]. Here, a counter (negative)-selection using an unrelated cell line was
applied to enhance selection pressure and remove aptamers present in the SELEX pool that bind to
receptors present in both positive and negative cell lines. Using this approach, five aptamers were
identified against cultured lymphoblastic leukemia cells. By utilizing two cell lines and incorporating
the negative selection, the authors hypothesized that new aptamers could be identified to recognize
surface markers uniquely expressed on the positive cell line. Upon selecting the target cell line,
the choice of the negative cell line predefines the nature of the molecular differences between the cell
lines; thus, the aptamers will be evolved according to the predefined difference between the two cell
lines [44]. This reasoning presupposes that such aptamers will detect new molecular fingerprints on
the target cell unique to a respective disease, leading the way to biomarker discovery [44]. It was also
hypothesized that the newly discovered biomarker would likely correlate with expression patterns of
the same proteins in patient primary cell samples obtained in a clinical setting with the same type of
disease [45]. One of the aptamers termed Sgc8 was later utilized as a capturing molecule to identify
the target protein [46]. Moreover, by introducing the concept of counter-selection utilizing B-cell line
Burkitt’s lymphoma to eliminate the accumulation of sequences biased towards membrane proteins,
Shangguan et al. and coworkers demonstrated that specific aptamers toward a single cell type could be
identified toward a specific cell line. This approach also addressed the issues of non-specific sequences
and lack of homology among families, both of which were encountered in the initial two studies
described above.
The introduction of live cell–SELEX simplified the SELEX method, allowing more laboratories
to implement SELEX technology as a method to generate aptamer-based molecular probes against
cells. The most important contribution of live cell–SELEX, however, is deeply rooted in the ability
to detect enrichment of the pool using flow cytometry without altering the conditions used in the
selection step (Figure 2). While aptamers are continuously compared to antibodies, an early hallmark
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of antibody success is associated with their use as effective diagnostic tools, not as therapeutics. This is
especially true for the diagnosis of hematopoietic diseases [47–49]. Similarly, the use of flow cytometry
in detecting enrichment and aptamer binding advanced the relevance of aptamers as robust diagnostic
tools. Also, the elimination of radioactive 32P labeling of pools to monitor the progress of selection
expanded these technologies to laboratories that previously lacked the specialized equipment.
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Figure 2. Outline of cell-SELEX with negative screening to increase selection pressure. The ability to
detect enrichment of the SELEX pool using flow cytometry without altering the conditions used in the
selection step enhanced the relevance of aptamers as diagnostic agents for hematopoietic diseases.
Next, aptamers selected using live cell–SELEX also showed specific binding when leukemia
cells were mixed with cells obtained from human peripheral blood mononuclear cell (PBMC)
samples. For the first time, Shangguan et al. further demonstrated the clinical utility of aptamers
in detecting primary leukemia samples [45]. In particular, using live cell-SELEX, protein tyrosine
kinase 7 (PTK7) was identified as the target of candidate aptamer Sgc8 [46]. In a follow-up study in
which counter-selection was eliminated, aptamer pools were enriched against Burkitt’s lymphoma cells,
demonstrating that aptamer pools could be enriched against whole cells to discover a panel of aptamers
against the dominant cell-surface targets [50]. Aptamer TD05, selected against Burkitt’s lymphoma
cells, was further modified as a capturing probe in a pull-down assay to discover cell-surface IgM as the
aptamer’s target [51]. Both of these initial examples further confirmed that aptamers selected against
whole cells could be used to profile cell lines for the differential expression of cell-surface molecules,
and related primary samples could also be detected utilizing flow cytometry. This is significant because
this technology is a state-of-the-art detection method for immunophenotyping using antibodies in
a clinical setting, and many laboratories have now used this approach to identify aptamers against
cell-surface targets [52–56].
More recently, live cell-SELEX has been implemented for the selection of aptamers against whole
cells, and using a glioblastoma cell line, a panel of RNA aptamers was generated using another variant
of live cell-SELEX termed differential SELEX [57]. Here, the idea is to introduce the negative selection
step before the positive selection. Another extension of live cell-SELEX is the use of an advanced
form of flow cytometry called fluorescence-activated cell sorting (FACS) [58]. Usually dead cells can
absorb single-stranded nucleic acid molecules, a process which greatly suppresses selection efficiency.
To circumvent these issues, FACS was utilized to discriminate live from dead cells at positive selection,
thus eliminating the dead cell population. This shows the effective enrichment of a SELEX library
against whole cells, as well as the enhanced efficiency of SELEX through sorting out the population of
dead cells. This technique also incorporates both positive and negative selection in one round to sort
out the negative and positive cells, leading to a more efficient enrichment.
Since the introduction of live cell-SELEX, studies reporting on the technology have increased
exponentially, and many aptamers have been identified utilizing this method, including aptamers
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with internalization capacity [59]. In addition, using an expanded genetic code, artificial nucleic acids
were introduced to select aptamers containing two expanded nucleotides not naturally available.
This recent SELEX innovation, termed Artificially Expanded Genetic Information System (AEGIS),
is a novel platform showing that aptamers with modified nucleic acids can also be utilized [60].
However, of the hundreds of aptamers generated thus far from live cell-SELEX, only a few targets
have been isolated and identified. Target identification of aptamers generated from live cell-SELEX is
commonly performed by proteomics analysis of aptamer affinity pull-down targets. Since cell-surface
membrane proteins have low solubility, these pull-down assays have, in many cases, failed [61].
Also, the amount of protein obtained in each pull-down experiment utilizing cell-surface molecules
with native expression levels is often very low, complicating mass spectrometry identification [61].
Thus, new variants of live cell-SELEX have been introduced to circumvent some of the issues of live
cell-SELEX with tailored approaches based on the end goal. This strategy is highly desirable, especially
when aptamers are intended for use in drug delivery.
6. Cell-Internalizing SELEX
By modifying live cell-SELEX to allow the isolation of aptamers with internalization capability,
cell-internalizing SELEX was introduced [62]. One of the key features of this method is the ability
to isolate ssRNA sequences exclusively based on their capacity to bind the cell-surface target and
their ability to rapidly internalize the cell in physiological conditions (Figure 3). Thus, this approach
effectively eliminates aptamers that lack internalizing ability and aptamers that only slowly internalize
into the cells, while favoring those that rapidly internalize as they bind their cognate receptor targets.
Using a derived cell line over-expressing Her2, a transmembrane receptor over-expressed in breast
cancer, as the positive cell line, and a cell line not expressing Her2, Theil et al. identified a panel
of aptamers against Her2 [62]. This method also utilized a stringent salt wash step to rule out the
possibility of aptamers remaining on the surface. Interestingly, three aptamers identified in this study
were shown to have affinity towards recombinant purified Her2.
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Figure 3. Schematic of cell-internalization SELEX. Cell-internalization SELEX was designed to isolate
ssRNA sequences exclusively based on their capacity to bind the cell-surface target and their ability to
rapidly internalize the cell in physiological conditions, while effectively eliminating aptamers that lack
internalizing ability and aptamers that only slowly internalize into the cells.
Although cell-internalizing SELEX demonstrated that aptamers could be isolated based on their
internalization ability, it is possible that some of those aptamers will be lost due to the complexity of
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the method itself. The requirement of engineering a cell line with the desired over-expressed receptor
and a cell line without the same receptor for the negative control makes this approach laborious
and limited. These issues were addressed in a recently reported variant of cell-internalizing SELEX
described by Laboni et al. [63]. Using nuclease-resistant 2′-fluoro-pyrimidines, an aptamer library was
first used for differential cell-SELEX to enrich the aptamer population toward the glioma-specific cell
line U87MG. After 13 rounds of differential cell–SELEX, aptamers with internalizing capacity were
isolated. The target of the dominant aptamer, GL56, as identified utilizing pull-down assay, appeared
to bind to the insulin receptor.
While these methods introduced alternative avenues to select aptamers based on the goal of
target identification, each approach has its own limitations. For example, cell-internalizing SELEX
requires the generation of two cloned cell lines, one that over-expresses the target and one that does not.
Moreover, the internalization of aptamers and isolation of aptamers, once they have been internalized,
is a complex and laborious process. Hybrid-SELEX requires over-expression and purification of surface
proteins, and it is possible that aptamers bound to multiple receptors at the “cross-over stage” will
be lost. Finally, aptamers generated using live cell–SELEX need post-SELEX manipulation of the
whole cell to identify the target protein. Difficulties associated in identification of target proteins of the
aptamers identified using live cell–SELEX have limited the potential application of these aptamers in
developing therapeutics or diagnostics.
7. Ligand-Guided Selection (LIGS)
When selecting aptamers against surface markers, it is important to use a target closer to its native
conformation [64,65]. Recently, another variant of live cell-SELEX, termed ligand-guided selection,
or LIGS, was introduced to identify aptamers against known surface proteins (Figure 4). Two initial
reports focused on selecting aptamers against two dominant markers on lymphoma and leukemia cells.
This method addresses some of the challenges associated with established SELEX methods against
cell-surface proteins. For example, LIGS identifies highly selective aptamers against a predetermined
epitope expressed on the cell surface at its native expression levels. Interrupting the selection and
enrichment process, LIGS introduces a strong, highly bivalent binder, such as a monoclonal antibody
(mAb), which interacts with its cognate epitope to outcompete and replace specific aptamers from an
enriched SELEX pool.
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Figure 4. Schematic of ligand-guided selection. This approach effectively utilizes secondary ligands to
selectively elute specific aptamers against a known surface marker.
Thus, the first advantage lies in a ligand having the capacity to initiate a conformational
switch resulting in destabilization of the aptamer-protein complex, in turn allowing the elution
of specific aptamers. For example, most growth factor receptors respond to the binding of growth
factor, which triggers the conformational switch, but small molecules and ions can also trigger the
conformational switch on cell-surface markers. This conformational switching of the target protein can
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effectively be utilized as an avenue to selectively elute specific aptamers. The second advantage lies in
the combinatorial nature of the SELEX libraries. For example, at any given concentration of a SELEX
pool, the individual aptamer concentration towards a specific cell-surface target is substantially
low. Thus, the introduction of the pre-existing ligand above its dissociation constant towards the
same surface target most likely out-competes the aptamers from this pool. Combining these two key
advantages, LIGS allows the selection of aptamers against a surface marker without requiring pre- or
post-SELEX sample manipulations to identify aptamer targets. The simplicity of selective elution
could also be utilized to identify aptamers using primary cell samples. Utilizing LIGS, aptamers were
identified against membrane IgM expressed on B-cell lymphoma and CD3 expressed in T cell leukemia.
Selective elution using a secondary ligand against the same target expands the capabilities of live
cell-SELEX. One of the challenges of LIGS, however, is its limited use in biomarker discovery since
the method is confined to selecting aptamers from known surface markers with known high-affinity
secondary ligands towards the same ligand.
8. Conclusions
Two key avenues characterize the most recent progress in the development of NAAs, one being
the introduction of modified nucleic acids to enhance the structural diversity and, hence, the affinity of
selected aptamers, and the other being the introduction of SELEX methods tailored towards a specific
application to select aptamers [66]. Significant progress has been made in developing modified NAs.
For example, Slow Off-rate Modified Aptamer (SOMAmer) protein-binding reagents combine the
properties of the structural diversity of amino acids to generate high-affinity modified nucleic acid
aptamers [67]. Next-generation aptamers, or X-aptamers (XAs), have been developed by either random
or direct modification, particularly of the 5-position of certain uridines on a monothophosphate
backbone of an aptamer. The approach uses chemical linkers that allow additional modification of
nucleic acid bases with “X-ligands”, to enhance the structural diversity [68]. Next, the method utilizes
the X-aptamer library conjugated to polystyrene beads, generating one-bead-one-sequence, to select
X-aptamers with high affinity against a number of targets. In another example, click chemistry was used
to attach azide sugars to an unnatural alkyne-containing uridine derivative, followed by successful
incorporation into SELEX from which glycosylated DNA aptamers were evolved. Using this method,
aptamers binding to the neutralizing HIV antibody 2G12 were identified [69,70]. Utilizing a similar but
extended approach termed click-SELEX, aptamers against Cycle 3-GFP (Green Fluorescence Protein)
were generated [71]. These examples show the potential application of modified aptamers against
cell-surface targets with the aim of developing therapeutic or diagnostic tools. The enhancement of
structural diversity is important in strengthening affinity and, hence, specificity towards the target.
However, despite success in diversifying the library, the identification of the specific aptamers against
respective targets heavily relies on the screening technology. Therefore, it is essential to improve both
the screening technology of SELEX and the diversity of SELEX libraries in order to address current
challenges and push the field of aptamer development forward.
With each milestone in the advancement of SELEX technology, this review summarizes how the
NAA field is rapidly evolving. In particular, significant progress has been made in pushing aptamer
selection technology toward generating aptamers against targets in their native state. Progress has also
been made in sequencing technologies, such as next-generation sequencing (NGS), and engineered
polymerases are utilized in PCR. Application of such improved technologies enables researchers
in the field to explore the potential of SELEX and the combinatorial library, which is the basis of
selection. Implementing flow cytometry has made it possible to detect the enrichment of SELEX
pools using cells under conditions identical to those at the in vitro step, allowing the generation of
high-affinity aptamers. Finally, the recently introduced LIGS technology allows the identification of
aptamers against a known surface target utilizing a competing secondary ligand against the same
target. With all these improvements, the future of NAA research will see considerable momentum
toward translational applications.
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